CD19 and acute lymphoblastic leukemia: Since ALL is associated with premature B-cells, B-cell specific differentiation markers; CD19, CD20, and CD22, are highly associated Ags that are used for diagnosing and targeting with immunotherapeutic agents (40, 45).